Salud financiera de hoja de balance de Alligator Bioscience

Salud financiera controles de criterios 3/6

Alligator Bioscience tiene un patrimonio de los accionistas total de SEK11.9M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK118.5M y SEK106.6M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr66.12m
Patrimonio	kr11.86m
Total pasivo	kr106.60m
Activos totales	kr118.45m

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Apr 11

Recent updates

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

Dec 01

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

Dec 21

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Jul 30

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Jan 06

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Apr 11

Estimating The Intrinsic Value Of Alligator Bioscience AB (publ) (STO:ATORX)

Feb 17

Have Insiders Been Buying Alligator Bioscience AB (publ) (STO:ATORX) Shares?

Jan 13

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

Dec 09

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK78.2M) de ATORX no cubren sus pasivos a corto plazo (SEK99.1M).

Pasivo a largo plazo: Los activos a corto plazo de ATORX (SEK78.2M) superan a sus pasivos a largo plazo (SEK7.5M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ATORX está libre de deudas.

Reducción de la deuda: ATORX no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ATORX tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ATORX tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.5% cada año

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de Alligator Bioscience

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Recent updates

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

New minor risk - Share price stability

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

New minor risk - Profitability

Third quarter 2023 earnings released

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Price target decreased by 19% to kr1.90

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Consensus revenue estimates increase by 11%

Price target decreased by 36% to kr2.33

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

High number of new directors

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021)

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: kr0.21 (vs kr0.41 loss in 2Q 2021)

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Vice Chairman of the Board recently bought kr152k worth of stock

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Consensus forecasts updated

Chief Executive Officer recently bought kr51k worth of stock

Price target decreased to kr2.80

Less than half of directors are independent

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Consensus revenue estimates increase by 255%

Alligator Bioscience AB (publ) to Report Q3, 2022 Results on Oct 20, 2022

Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer

Alligator Bioscience Announces Optimize-1 Trial Update

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: kr0.43 loss per share (vs kr0.43 loss in 3Q 2020)

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Consensus revenue estimates increase to kr5.00m

Alligator Bioscience AB (Publ) Initiates A Phase II Trial with Mitazalimab, and Drug Candidate Ator-1017 Is Soon to Follow

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Independent Director Kenth Petersson has left the company

Independent Director Kirsten Drejer has left the company

Independent Director Jonas Sjögren has left the company

Independent Director Ulrika Danielsson has left the company

Independent Chairman Peter Benson has left the company

Alligator Bioscience Presents Positive Phase I Data At ASCO for Its 4-1BB Agonist Drug Candidate ATOR-1017

Independent Director recently bought kr1.1m worth of stock

Independent Director recently bought kr1.1m worth of stock

Independent Director recently bought kr1.1m worth of stock

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Full year 2020 earnings released: kr2.01 loss per share (vs kr2.94 loss in FY 2019)

Alligator Bioscience Appoints Søren Bregenholt as New CEO

Alligator Bioscience to Develop Tumour-Directed Immunotherapies in Clinical Phase II